Rockin Robin SongFlying The Web For News.
RobinPost Logo Amazon Prime Deals





Globe NewsWire News Distribution Service


SAN MATEO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Channelscaler, the category-defining platform for modern partner ecosystems, announced today that it is now available in the Microsoft Marketplace. The listing offers enterprises a strategic advantage by enabling them to seamlessly acquire, deploy, and pay for Channelscaler’s AI-driven PRM and channel automation platform.


Posted: 2026-08-05 13:04:00

Get Full News Story On GlobeNewsWire Press Release Service




More News From This Category
Press Release: Dimensional Fund Advisors Ltd. : Form 8.3 - DCC Energy PLC - Ordinary Shares
Wed, 05 Aug 2026 10:07:34 +0000

FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDERRULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVERRULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANTSECURITIES REPRESENTING 1% OR MORE

Read More ...


Press Release: CallTower Launches the Upfront Advantage, an Exclusive Incentive Program for Partners
Wed, 05 Aug 2026 07:07:50 +0000

SALT LAKE CITY, UT, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CallTower, a global leader in delivering unified communications, contact center, and collaboration solutions, today announced the launch of its new Upfront Advantage Partner Program, an exclusive, invite-only initiative designed to help partners accelerate revenue realization and drive long-term growth through new customer acquisitions.

Read More ...


Press Release: Snail, Inc. 子公司 Egofold 於 Ai4 2026 推出新一代 AI 遊戲夥伴 AI Ranch 及 NHPs™
Wed, 05 Aug 2026 04:07:36 +0000

加州卡爾弗城, Aug. 05, 2026 (GLOBE NEWSWIRE) -- 全球領先的獨立互動數碼娛樂開發商與發行商 Snail, Inc. (Nasdaq: SNAL)(下稱「Snail Games」或「公司」)今日宣佈,其子公司 Egofold 將在 2026 年 8 月 4 日至 6 日於拉斯維加斯舉行的 Ai4 2026 上,首度公開展示人工智能企劃 AI Ranch 及 NHPs™。

Read More ...


Press Release: Grace Therapeutics Announces $10 Million Private Placement
Wed, 05 Aug 2026 01:07:50 +0000

PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it has entered into a securities purchase agreement…

Read More ...


Related Bing News Results





















Blow Us A Whistle


RobinsPost Print On Demand Refund Policy With Printify
Printify

Related Product Search/Búsqueda de productos relacionados

Amazon Logo